Sarah Cannon Research Institute shared a post on LinkedIn:
“Charles Anderson, MD, Executive Member, Gynecologic Cancer Research Executive Committee, SCRI at Willamette Valley Cancer Institute and Research Center, discusses exciting advancements happening in gynecological cancer, the critical role of specialized care, and the power of early intervention for improving patients’ health outcomes.
Imagine the moment when a patient first hears the word ‘cancer.’ For many, it’s a moment of disbelief and fear. I remember a patient in her 30s, who, while 17 weeks pregnant, faced the daunting decision of undergoing surgery and chemotherapy to treat her metastatic ovarian cancer. The courage she displayed, balancing her own health with the life of her unborn child, was nothing short of extraordinary. We performed the surgery at 18 weeks, followed by urgent chemotherapy a few weeks later. Eventually she delivered a healthy baby at term gestation. Today, she is cancer-free and thriving, a testament to the power of early aggressive intervention and advanced treatment.
This is just one example as to why I love what I do. As a gynecological oncologist, I’m honored to accompany many brave women on their journeys through various gynecological malignancies. Each September, during Ovarian Cancer Awareness Month, we come together to shed light on these conditions that often remain in the shadows, despite their profound impact on countless lives.
Gynecological cancers, including ovarian, cervical, endometrial, and vulvar cancers, often masked by vague symptoms such as bloating, frequent urination, abnormal discharge, constipation, and pelvic pain, are frequently diagnosed at later stages due to these subtle indicators. While about 25% of cases of ovarian cancer are genetic, the majority are influenced by lifestyle factors or occur without any clear cause. Early-stage detection gives patients a chance of cure, but this drops significantly if the cancer is more advanced. That is why intentional screening and open communication with patients are critical.
The landscape of gynecological cancer treatment has entered what I call the “Golden Age” of therapeutics. In the past few years alone, we’ve witnessed a surge in revolutionary drugs and treatments. Additionally, thanks to clinical trial participation, treatments originally developed for other cancers, such as lung and breast cancer, are being tested for their efficacy in treating gynecological cancers. From next-generation therapies to antibody-drug conjugates, these advancements are transforming our approach to care, often resulting in fewer side effects than traditional chemotherapy resulting in better quality of life on treatment.
Advancements like these are why Sarah Cannon Research Institute (SCRI) advocates for clinical trial participation. Our goal as doctors is to identify and provide the best treatment plan for the patient and minimize any negative impact it could have on their health physically, mentally, and financially. For example, many years ago, one of my patients participated in one of the first immunotherapy clinical trials for late-stage ovarian cancer. Remarkably, she achieved remission and currently is cancer free several years after stopping treatment – a testament to the transformative potential of innovative research.
However, minimizing the impact of cancer treatment also includes overcoming social and financial barriers. Access to care can be significantly hindered by geographic location. SCRI’s network helps bridge these gaps by expanding access to clinical trials at the local level even in rural, often underserved, areas ensuring that patients everywhere have the opportunity to participate in cutting-edge research.
The journey through cancer is challenging, but I find solace in the hope and support we provide for our patients. Each story of survival and recovery fuels our commitment to improving care and advancing treatments. As we mark Gynecological and Ovarian Cancer Awareness Month, let us remember that behind every statistic is a story of resilience, hope, and the relentless pursuit of a cure.
Together, we continue to navigate these challenges, driven by the belief that every patient deserves the best possible chance at life.”
More posts featuring Sarah Cannon Research Institute.